nodes	percent_of_prediction	percent_of_DWPC	metapath
Glycopyrrolate—CHRM3—ureter—colon cancer	0.109	0.476	CbGeAlD
Glycopyrrolate—CHRM3—muscle of abdomen—colon cancer	0.0787	0.343	CbGeAlD
Glycopyrrolate—CHRM5—epithelium—colon cancer	0.0168	0.073	CbGeAlD
Glycopyrrolate—Intestinal obstruction—Vincristine—colon cancer	0.0133	0.0172	CcSEcCtD
Glycopyrrolate—Intestinal obstruction—Irinotecan—colon cancer	0.0129	0.0168	CcSEcCtD
Glycopyrrolate—Nystagmus—Vincristine—colon cancer	0.0127	0.0164	CcSEcCtD
Glycopyrrolate—Nystagmus—Fluorouracil—colon cancer	0.0118	0.0153	CcSEcCtD
Glycopyrrolate—CHRM3—smooth muscle tissue—colon cancer	0.00903	0.0393	CbGeAlD
Glycopyrrolate—CHRM3—renal system—colon cancer	0.00869	0.0378	CbGeAlD
Glycopyrrolate—Intestinal obstruction—Capecitabine—colon cancer	0.00865	0.0112	CcSEcCtD
Glycopyrrolate—Photophobia—Fluorouracil—colon cancer	0.00792	0.0103	CcSEcCtD
Glycopyrrolate—Ventricular fibrillation—Capecitabine—colon cancer	0.0077	0.00999	CcSEcCtD
Glycopyrrolate—Ageusia—Capecitabine—colon cancer	0.00727	0.00944	CcSEcCtD
Glycopyrrolate—CHRM3—digestive system—colon cancer	0.00713	0.031	CbGeAlD
Glycopyrrolate—Anaphylactoid reaction—Irinotecan—colon cancer	0.0066	0.00857	CcSEcCtD
Glycopyrrolate—Pain in extremity—Vincristine—colon cancer	0.00656	0.00852	CcSEcCtD
Glycopyrrolate—Cardiac arrest—Vincristine—colon cancer	0.00624	0.0081	CcSEcCtD
Glycopyrrolate—Urinary retention—Vincristine—colon cancer	0.00624	0.0081	CcSEcCtD
Glycopyrrolate—Dehydration—Vincristine—colon cancer	0.0061	0.00792	CcSEcCtD
Glycopyrrolate—Cardiac arrest—Irinotecan—colon cancer	0.00608	0.00789	CcSEcCtD
Glycopyrrolate—Dehydration—Irinotecan—colon cancer	0.00594	0.00772	CcSEcCtD
Glycopyrrolate—Injection site reaction—Capecitabine—colon cancer	0.00586	0.00761	CcSEcCtD
Glycopyrrolate—Irritability—Fluorouracil—colon cancer	0.00584	0.00759	CcSEcCtD
Glycopyrrolate—Cardiac arrest—Fluorouracil—colon cancer	0.00582	0.00756	CcSEcCtD
Glycopyrrolate—Dry skin—Fluorouracil—colon cancer	0.00561	0.00728	CcSEcCtD
Glycopyrrolate—Abdominal distension—Irinotecan—colon cancer	0.00556	0.00722	CcSEcCtD
Glycopyrrolate—Nasopharyngitis—Fluorouracil—colon cancer	0.00547	0.00711	CcSEcCtD
Glycopyrrolate—Dysuria—Vincristine—colon cancer	0.0053	0.00689	CcSEcCtD
Glycopyrrolate—Erectile dysfunction—Vincristine—colon cancer	0.00522	0.00678	CcSEcCtD
Glycopyrrolate—Upper respiratory tract infection—Irinotecan—colon cancer	0.00513	0.00667	CcSEcCtD
Glycopyrrolate—Pneumonia—Vincristine—colon cancer	0.00509	0.0066	CcSEcCtD
Glycopyrrolate—Pneumonia—Irinotecan—colon cancer	0.00495	0.00643	CcSEcCtD
Glycopyrrolate—Upper respiratory tract infection—Fluorouracil—colon cancer	0.00492	0.00638	CcSEcCtD
Glycopyrrolate—Sweating—Vincristine—colon cancer	0.00485	0.0063	CcSEcCtD
Glycopyrrolate—Gastroenteritis—Capecitabine—colon cancer	0.00483	0.00627	CcSEcCtD
Glycopyrrolate—Pneumonia—Fluorouracil—colon cancer	0.00475	0.00616	CcSEcCtD
Glycopyrrolate—Sweating—Irinotecan—colon cancer	0.00472	0.00613	CcSEcCtD
Glycopyrrolate—Infestation—Fluorouracil—colon cancer	0.00472	0.00612	CcSEcCtD
Glycopyrrolate—Infestation NOS—Fluorouracil—colon cancer	0.00472	0.00612	CcSEcCtD
Glycopyrrolate—Urinary tract infection—Fluorouracil—colon cancer	0.00459	0.00595	CcSEcCtD
Glycopyrrolate—Hypoaesthesia—Vincristine—colon cancer	0.00452	0.00587	CcSEcCtD
Glycopyrrolate—Atrial fibrillation—Capecitabine—colon cancer	0.00451	0.00586	CcSEcCtD
Glycopyrrolate—Urinary tract disorder—Vincristine—colon cancer	0.00448	0.00582	CcSEcCtD
Glycopyrrolate—Connective tissue disorder—Vincristine—colon cancer	0.00446	0.00579	CcSEcCtD
Glycopyrrolate—Urethral disorder—Vincristine—colon cancer	0.00445	0.00578	CcSEcCtD
Glycopyrrolate—Epistaxis—Fluorouracil—colon cancer	0.00445	0.00578	CcSEcCtD
Glycopyrrolate—Rhinitis—Irinotecan—colon cancer	0.00443	0.00576	CcSEcCtD
Glycopyrrolate—Sinusitis—Fluorouracil—colon cancer	0.00443	0.00575	CcSEcCtD
Glycopyrrolate—Connective tissue disorder—Irinotecan—colon cancer	0.00435	0.00564	CcSEcCtD
Glycopyrrolate—Cystitis noninfective—Methotrexate—colon cancer	0.00429	0.00556	CcSEcCtD
Glycopyrrolate—Pain in extremity—Capecitabine—colon cancer	0.00428	0.00555	CcSEcCtD
Glycopyrrolate—Rhinitis—Fluorouracil—colon cancer	0.00425	0.00551	CcSEcCtD
Glycopyrrolate—Cystitis—Methotrexate—colon cancer	0.00424	0.0055	CcSEcCtD
Glycopyrrolate—Cardiac disorder—Vincristine—colon cancer	0.00421	0.00547	CcSEcCtD
Glycopyrrolate—Hypoaesthesia—Fluorouracil—colon cancer	0.00421	0.00547	CcSEcCtD
Glycopyrrolate—Cardiac disorder—Irinotecan—colon cancer	0.0041	0.00533	CcSEcCtD
Glycopyrrolate—Flushing—Irinotecan—colon cancer	0.0041	0.00533	CcSEcCtD
Glycopyrrolate—Mediastinal disorder—Vincristine—colon cancer	0.00409	0.00531	CcSEcCtD
Glycopyrrolate—Irritability—Capecitabine—colon cancer	0.00408	0.0053	CcSEcCtD
Glycopyrrolate—Urinary retention—Capecitabine—colon cancer	0.00407	0.00528	CcSEcCtD
Glycopyrrolate—Cardiac arrest—Capecitabine—colon cancer	0.00407	0.00528	CcSEcCtD
Glycopyrrolate—Mood swings—Capecitabine—colon cancer	0.00405	0.00526	CcSEcCtD
Glycopyrrolate—Mediastinal disorder—Irinotecan—colon cancer	0.00399	0.00517	CcSEcCtD
Glycopyrrolate—Dehydration—Capecitabine—colon cancer	0.00398	0.00517	CcSEcCtD
Glycopyrrolate—Mental disorder—Vincristine—colon cancer	0.00398	0.00516	CcSEcCtD
Glycopyrrolate—Bladder pain—Methotrexate—colon cancer	0.00397	0.00515	CcSEcCtD
Glycopyrrolate—Dry skin—Capecitabine—colon cancer	0.00392	0.00509	CcSEcCtD
Glycopyrrolate—Nasopharyngitis—Capecitabine—colon cancer	0.00383	0.00497	CcSEcCtD
Glycopyrrolate—Flatulence—Irinotecan—colon cancer	0.00379	0.00492	CcSEcCtD
Glycopyrrolate—Abdominal distension—Capecitabine—colon cancer	0.00372	0.00483	CcSEcCtD
Glycopyrrolate—Erythema—Fluorouracil—colon cancer	0.00369	0.00479	CcSEcCtD
Glycopyrrolate—Agitation—Vincristine—colon cancer	0.00363	0.00472	CcSEcCtD
Glycopyrrolate—Abdominal discomfort—Capecitabine—colon cancer	0.00354	0.0046	CcSEcCtD
Glycopyrrolate—Vision blurred—Fluorouracil—colon cancer	0.00347	0.00451	CcSEcCtD
Glycopyrrolate—Dysuria—Capecitabine—colon cancer	0.00346	0.00449	CcSEcCtD
Glycopyrrolate—Upper respiratory tract infection—Capecitabine—colon cancer	0.00344	0.00446	CcSEcCtD
Glycopyrrolate—Convulsion—Vincristine—colon cancer	0.00342	0.00445	CcSEcCtD
Glycopyrrolate—Hypertension—Vincristine—colon cancer	0.00341	0.00443	CcSEcCtD
Glycopyrrolate—Hyperglycaemia—Capecitabine—colon cancer	0.00334	0.00433	CcSEcCtD
Glycopyrrolate—Hypertension—Irinotecan—colon cancer	0.00332	0.00431	CcSEcCtD
Glycopyrrolate—Pneumonia—Capecitabine—colon cancer	0.00332	0.0043	CcSEcCtD
Glycopyrrolate—Infestation NOS—Capecitabine—colon cancer	0.0033	0.00428	CcSEcCtD
Glycopyrrolate—Infestation—Capecitabine—colon cancer	0.0033	0.00428	CcSEcCtD
Glycopyrrolate—Anaphylactoid reaction—Methotrexate—colon cancer	0.00329	0.00427	CcSEcCtD
Glycopyrrolate—Anaphylactic shock—Vincristine—colon cancer	0.00323	0.00419	CcSEcCtD
Glycopyrrolate—Oedema—Vincristine—colon cancer	0.00323	0.00419	CcSEcCtD
Glycopyrrolate—Infection—Vincristine—colon cancer	0.0032	0.00416	CcSEcCtD
Glycopyrrolate—Urinary tract infection—Capecitabine—colon cancer	0.0032	0.00416	CcSEcCtD
Glycopyrrolate—Convulsion—Fluorouracil—colon cancer	0.00319	0.00415	CcSEcCtD
Glycopyrrolate—Confusional state—Irinotecan—colon cancer	0.00317	0.00411	CcSEcCtD
Glycopyrrolate—Nervous system disorder—Vincristine—colon cancer	0.00316	0.00411	CcSEcCtD
Glycopyrrolate—Anaphylactic shock—Irinotecan—colon cancer	0.00314	0.00408	CcSEcCtD
Glycopyrrolate—Oedema—Irinotecan—colon cancer	0.00314	0.00408	CcSEcCtD
Glycopyrrolate—Infection—Irinotecan—colon cancer	0.00312	0.00405	CcSEcCtD
Glycopyrrolate—Hyperhidrosis—Vincristine—colon cancer	0.00312	0.00405	CcSEcCtD
Glycopyrrolate—Epistaxis—Capecitabine—colon cancer	0.00311	0.00404	CcSEcCtD
Glycopyrrolate—Nervous system disorder—Irinotecan—colon cancer	0.00308	0.004	CcSEcCtD
Glycopyrrolate—Irritability—Methotrexate—colon cancer	0.00304	0.00395	CcSEcCtD
Glycopyrrolate—Hyperhidrosis—Irinotecan—colon cancer	0.00304	0.00394	CcSEcCtD
Glycopyrrolate—Confusional state—Fluorouracil—colon cancer	0.00303	0.00394	CcSEcCtD
Glycopyrrolate—Mood swings—Methotrexate—colon cancer	0.00302	0.00392	CcSEcCtD
Glycopyrrolate—Hypotension—Vincristine—colon cancer	0.00301	0.00391	CcSEcCtD
Glycopyrrolate—Oedema—Fluorouracil—colon cancer	0.00301	0.00391	CcSEcCtD
Glycopyrrolate—Anaphylactic shock—Fluorouracil—colon cancer	0.00301	0.00391	CcSEcCtD
Glycopyrrolate—Infection—Fluorouracil—colon cancer	0.00299	0.00388	CcSEcCtD
Glycopyrrolate—Rhinitis—Capecitabine—colon cancer	0.00297	0.00385	CcSEcCtD
Glycopyrrolate—Nervous system disorder—Fluorouracil—colon cancer	0.00295	0.00383	CcSEcCtD
Glycopyrrolate—Hypoaesthesia—Capecitabine—colon cancer	0.00294	0.00382	CcSEcCtD
Glycopyrrolate—Tachycardia—Fluorouracil—colon cancer	0.00294	0.00381	CcSEcCtD
Glycopyrrolate—Hypotension—Irinotecan—colon cancer	0.00294	0.00381	CcSEcCtD
Glycopyrrolate—Urinary tract disorder—Capecitabine—colon cancer	0.00292	0.00379	CcSEcCtD
Glycopyrrolate—Insomnia—Vincristine—colon cancer	0.00292	0.00379	CcSEcCtD
Glycopyrrolate—Connective tissue disorder—Capecitabine—colon cancer	0.00291	0.00378	CcSEcCtD
Glycopyrrolate—Urethral disorder—Capecitabine—colon cancer	0.0029	0.00377	CcSEcCtD
Glycopyrrolate—Insomnia—Irinotecan—colon cancer	0.00284	0.00369	CcSEcCtD
Glycopyrrolate—Hypotension—Fluorouracil—colon cancer	0.00281	0.00365	CcSEcCtD
Glycopyrrolate—Somnolence—Irinotecan—colon cancer	0.00279	0.00363	CcSEcCtD
Glycopyrrolate—Gastrointestinal disorder—Vincristine—colon cancer	0.00279	0.00362	CcSEcCtD
Glycopyrrolate—Fatigue—Vincristine—colon cancer	0.00278	0.00361	CcSEcCtD
Glycopyrrolate—Dyspepsia—Irinotecan—colon cancer	0.00277	0.00359	CcSEcCtD
Glycopyrrolate—Constipation—Vincristine—colon cancer	0.00276	0.00358	CcSEcCtD
Glycopyrrolate—Pain—Vincristine—colon cancer	0.00276	0.00358	CcSEcCtD
Glycopyrrolate—Flushing—Capecitabine—colon cancer	0.00275	0.00357	CcSEcCtD
Glycopyrrolate—Cardiac disorder—Capecitabine—colon cancer	0.00275	0.00357	CcSEcCtD
Glycopyrrolate—Insomnia—Fluorouracil—colon cancer	0.00272	0.00353	CcSEcCtD
Glycopyrrolate—Gastrointestinal disorder—Irinotecan—colon cancer	0.00271	0.00352	CcSEcCtD
Glycopyrrolate—Fatigue—Irinotecan—colon cancer	0.00271	0.00352	CcSEcCtD
Glycopyrrolate—Pain—Irinotecan—colon cancer	0.00269	0.00349	CcSEcCtD
Glycopyrrolate—Constipation—Irinotecan—colon cancer	0.00269	0.00349	CcSEcCtD
Glycopyrrolate—Somnolence—Fluorouracil—colon cancer	0.00268	0.00347	CcSEcCtD
Glycopyrrolate—Mediastinal disorder—Capecitabine—colon cancer	0.00267	0.00346	CcSEcCtD
Glycopyrrolate—Dyspepsia—Fluorouracil—colon cancer	0.00265	0.00344	CcSEcCtD
Glycopyrrolate—Abdominal discomfort—Methotrexate—colon cancer	0.00264	0.00343	CcSEcCtD
Glycopyrrolate—Gastrointestinal pain—Vincristine—colon cancer	0.00264	0.00342	CcSEcCtD
Glycopyrrolate—Gastrointestinal disorder—Fluorouracil—colon cancer	0.0026	0.00337	CcSEcCtD
Glycopyrrolate—Mental disorder—Capecitabine—colon cancer	0.00259	0.00337	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Irinotecan—colon cancer	0.00259	0.00336	CcSEcCtD
Glycopyrrolate—Erythema—Capecitabine—colon cancer	0.00258	0.00334	CcSEcCtD
Glycopyrrolate—Malnutrition—Capecitabine—colon cancer	0.00258	0.00334	CcSEcCtD
Glycopyrrolate—Dysuria—Methotrexate—colon cancer	0.00257	0.00334	CcSEcCtD
Glycopyrrolate—Pain—Fluorouracil—colon cancer	0.00257	0.00334	CcSEcCtD
Glycopyrrolate—Gastrointestinal pain—Irinotecan—colon cancer	0.00257	0.00334	CcSEcCtD
Glycopyrrolate—Upper respiratory tract infection—Methotrexate—colon cancer	0.00256	0.00332	CcSEcCtD
Glycopyrrolate—Abdominal pain—Vincristine—colon cancer	0.00255	0.00331	CcSEcCtD
Glycopyrrolate—Body temperature increased—Vincristine—colon cancer	0.00255	0.00331	CcSEcCtD
Glycopyrrolate—Flatulence—Capecitabine—colon cancer	0.00254	0.0033	CcSEcCtD
Glycopyrrolate—Erectile dysfunction—Methotrexate—colon cancer	0.00254	0.00329	CcSEcCtD
Glycopyrrolate—Dysgeusia—Capecitabine—colon cancer	0.00252	0.00328	CcSEcCtD
Glycopyrrolate—Abdominal pain—Irinotecan—colon cancer	0.00248	0.00322	CcSEcCtD
Glycopyrrolate—Body temperature increased—Irinotecan—colon cancer	0.00248	0.00322	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Fluorouracil—colon cancer	0.00248	0.00322	CcSEcCtD
Glycopyrrolate—Pneumonia—Methotrexate—colon cancer	0.00247	0.0032	CcSEcCtD
Glycopyrrolate—Drowsiness—Methotrexate—colon cancer	0.00245	0.00319	CcSEcCtD
Glycopyrrolate—Infestation NOS—Methotrexate—colon cancer	0.00245	0.00319	CcSEcCtD
Glycopyrrolate—Infestation—Methotrexate—colon cancer	0.00245	0.00319	CcSEcCtD
Glycopyrrolate—Vision blurred—Capecitabine—colon cancer	0.00243	0.00315	CcSEcCtD
Glycopyrrolate—Urticaria—Fluorouracil—colon cancer	0.00239	0.0031	CcSEcCtD
Glycopyrrolate—Body temperature increased—Fluorouracil—colon cancer	0.00238	0.00309	CcSEcCtD
Glycopyrrolate—Hypersensitivity—Vincristine—colon cancer	0.00238	0.00309	CcSEcCtD
Glycopyrrolate—Sweating—Methotrexate—colon cancer	0.00235	0.00305	CcSEcCtD
Glycopyrrolate—Epistaxis—Methotrexate—colon cancer	0.00231	0.00301	CcSEcCtD
Glycopyrrolate—Hypersensitivity—Irinotecan—colon cancer	0.00231	0.003	CcSEcCtD
Glycopyrrolate—Asthenia—Vincristine—colon cancer	0.00231	0.003	CcSEcCtD
Glycopyrrolate—Palpitations—Capecitabine—colon cancer	0.00228	0.00296	CcSEcCtD
Glycopyrrolate—Asthenia—Irinotecan—colon cancer	0.00225	0.00293	CcSEcCtD
Glycopyrrolate—Hypertension—Capecitabine—colon cancer	0.00222	0.00289	CcSEcCtD
Glycopyrrolate—Hypersensitivity—Fluorouracil—colon cancer	0.00222	0.00288	CcSEcCtD
Glycopyrrolate—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.00218	0.00283	CcSEcCtD
Glycopyrrolate—Urinary tract disorder—Methotrexate—colon cancer	0.00218	0.00282	CcSEcCtD
Glycopyrrolate—Urethral disorder—Methotrexate—colon cancer	0.00216	0.0028	CcSEcCtD
Glycopyrrolate—Dry mouth—Capecitabine—colon cancer	0.00215	0.00278	CcSEcCtD
Glycopyrrolate—Dizziness—Vincristine—colon cancer	0.00213	0.00277	CcSEcCtD
Glycopyrrolate—Pruritus—Fluorouracil—colon cancer	0.00213	0.00276	CcSEcCtD
Glycopyrrolate—Confusional state—Capecitabine—colon cancer	0.00212	0.00275	CcSEcCtD
Glycopyrrolate—Oedema—Capecitabine—colon cancer	0.0021	0.00273	CcSEcCtD
Glycopyrrolate—Infection—Capecitabine—colon cancer	0.00209	0.00271	CcSEcCtD
Glycopyrrolate—Dizziness—Irinotecan—colon cancer	0.00208	0.0027	CcSEcCtD
Glycopyrrolate—Nervous system disorder—Capecitabine—colon cancer	0.00206	0.00268	CcSEcCtD
Glycopyrrolate—Tachycardia—Capecitabine—colon cancer	0.00205	0.00266	CcSEcCtD
Glycopyrrolate—Vomiting—Vincristine—colon cancer	0.00205	0.00266	CcSEcCtD
Glycopyrrolate—Cardiac disorder—Methotrexate—colon cancer	0.00204	0.00265	CcSEcCtD
Glycopyrrolate—Skin disorder—Capecitabine—colon cancer	0.00204	0.00265	CcSEcCtD
Glycopyrrolate—Rash—Vincristine—colon cancer	0.00203	0.00264	CcSEcCtD
Glycopyrrolate—Hyperhidrosis—Capecitabine—colon cancer	0.00203	0.00264	CcSEcCtD
Glycopyrrolate—Dermatitis—Vincristine—colon cancer	0.00203	0.00264	CcSEcCtD
Glycopyrrolate—Headache—Vincristine—colon cancer	0.00202	0.00262	CcSEcCtD
Glycopyrrolate—Vomiting—Irinotecan—colon cancer	0.002	0.00259	CcSEcCtD
Glycopyrrolate—Dizziness—Fluorouracil—colon cancer	0.00199	0.00258	CcSEcCtD
Glycopyrrolate—Mediastinal disorder—Methotrexate—colon cancer	0.00199	0.00258	CcSEcCtD
Glycopyrrolate—Rash—Irinotecan—colon cancer	0.00198	0.00257	CcSEcCtD
Glycopyrrolate—Dermatitis—Irinotecan—colon cancer	0.00198	0.00257	CcSEcCtD
Glycopyrrolate—Headache—Irinotecan—colon cancer	0.00197	0.00256	CcSEcCtD
Glycopyrrolate—Hypotension—Capecitabine—colon cancer	0.00196	0.00255	CcSEcCtD
Glycopyrrolate—Mental disorder—Methotrexate—colon cancer	0.00193	0.00251	CcSEcCtD
Glycopyrrolate—Erythema—Methotrexate—colon cancer	0.00192	0.00249	CcSEcCtD
Glycopyrrolate—Malnutrition—Methotrexate—colon cancer	0.00192	0.00249	CcSEcCtD
Glycopyrrolate—Nausea—Vincristine—colon cancer	0.00192	0.00249	CcSEcCtD
Glycopyrrolate—Vomiting—Fluorouracil—colon cancer	0.00191	0.00248	CcSEcCtD
Glycopyrrolate—Insomnia—Capecitabine—colon cancer	0.0019	0.00247	CcSEcCtD
Glycopyrrolate—Rash—Fluorouracil—colon cancer	0.0019	0.00246	CcSEcCtD
Glycopyrrolate—Dermatitis—Fluorouracil—colon cancer	0.0019	0.00246	CcSEcCtD
Glycopyrrolate—Headache—Fluorouracil—colon cancer	0.00189	0.00245	CcSEcCtD
Glycopyrrolate—Dysgeusia—Methotrexate—colon cancer	0.00188	0.00244	CcSEcCtD
Glycopyrrolate—Nausea—Irinotecan—colon cancer	0.00187	0.00242	CcSEcCtD
Glycopyrrolate—Dyspepsia—Capecitabine—colon cancer	0.00185	0.0024	CcSEcCtD
Glycopyrrolate—Gastrointestinal disorder—Capecitabine—colon cancer	0.00182	0.00236	CcSEcCtD
Glycopyrrolate—Fatigue—Capecitabine—colon cancer	0.00181	0.00235	CcSEcCtD
Glycopyrrolate—Vision blurred—Methotrexate—colon cancer	0.00181	0.00235	CcSEcCtD
Glycopyrrolate—Pain—Capecitabine—colon cancer	0.0018	0.00233	CcSEcCtD
Glycopyrrolate—Constipation—Capecitabine—colon cancer	0.0018	0.00233	CcSEcCtD
Glycopyrrolate—Nausea—Fluorouracil—colon cancer	0.00179	0.00232	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Capecitabine—colon cancer	0.00173	0.00225	CcSEcCtD
Glycopyrrolate—Gastrointestinal pain—Capecitabine—colon cancer	0.00172	0.00223	CcSEcCtD
Glycopyrrolate—Urticaria—Capecitabine—colon cancer	0.00167	0.00217	CcSEcCtD
Glycopyrrolate—Abdominal pain—Capecitabine—colon cancer	0.00166	0.00216	CcSEcCtD
Glycopyrrolate—Body temperature increased—Capecitabine—colon cancer	0.00166	0.00216	CcSEcCtD
Glycopyrrolate—Convulsion—Methotrexate—colon cancer	0.00166	0.00216	CcSEcCtD
Glycopyrrolate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	0.00162	0.00211	CcSEcCtD
Glycopyrrolate—Confusional state—Methotrexate—colon cancer	0.00158	0.00205	CcSEcCtD
Glycopyrrolate—Anaphylactic shock—Methotrexate—colon cancer	0.00157	0.00203	CcSEcCtD
Glycopyrrolate—Infection—Methotrexate—colon cancer	0.00156	0.00202	CcSEcCtD
Glycopyrrolate—Hypersensitivity—Capecitabine—colon cancer	0.00155	0.00201	CcSEcCtD
Glycopyrrolate—Nervous system disorder—Methotrexate—colon cancer	0.00154	0.00199	CcSEcCtD
Glycopyrrolate—Skin disorder—Methotrexate—colon cancer	0.00152	0.00197	CcSEcCtD
Glycopyrrolate—Hyperhidrosis—Methotrexate—colon cancer	0.00151	0.00196	CcSEcCtD
Glycopyrrolate—Asthenia—Capecitabine—colon cancer	0.00151	0.00196	CcSEcCtD
Glycopyrrolate—Pruritus—Capecitabine—colon cancer	0.00149	0.00193	CcSEcCtD
Glycopyrrolate—Hypotension—Methotrexate—colon cancer	0.00146	0.0019	CcSEcCtD
Glycopyrrolate—Insomnia—Methotrexate—colon cancer	0.00142	0.00184	CcSEcCtD
Glycopyrrolate—Somnolence—Methotrexate—colon cancer	0.00139	0.00181	CcSEcCtD
Glycopyrrolate—Dizziness—Capecitabine—colon cancer	0.00139	0.00181	CcSEcCtD
Glycopyrrolate—Dyspepsia—Methotrexate—colon cancer	0.00138	0.00179	CcSEcCtD
Glycopyrrolate—Gastrointestinal disorder—Methotrexate—colon cancer	0.00135	0.00175	CcSEcCtD
Glycopyrrolate—Fatigue—Methotrexate—colon cancer	0.00135	0.00175	CcSEcCtD
Glycopyrrolate—Pain—Methotrexate—colon cancer	0.00134	0.00174	CcSEcCtD
Glycopyrrolate—Vomiting—Capecitabine—colon cancer	0.00134	0.00174	CcSEcCtD
Glycopyrrolate—Rash—Capecitabine—colon cancer	0.00133	0.00172	CcSEcCtD
Glycopyrrolate—Dermatitis—Capecitabine—colon cancer	0.00132	0.00172	CcSEcCtD
Glycopyrrolate—Headache—Capecitabine—colon cancer	0.00132	0.00171	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Methotrexate—colon cancer	0.00129	0.00167	CcSEcCtD
Glycopyrrolate—Gastrointestinal pain—Methotrexate—colon cancer	0.00128	0.00166	CcSEcCtD
Glycopyrrolate—Nausea—Capecitabine—colon cancer	0.00125	0.00162	CcSEcCtD
Glycopyrrolate—Urticaria—Methotrexate—colon cancer	0.00124	0.00161	CcSEcCtD
Glycopyrrolate—Body temperature increased—Methotrexate—colon cancer	0.00124	0.00161	CcSEcCtD
Glycopyrrolate—Abdominal pain—Methotrexate—colon cancer	0.00124	0.00161	CcSEcCtD
Glycopyrrolate—Hypersensitivity—Methotrexate—colon cancer	0.00115	0.0015	CcSEcCtD
Glycopyrrolate—Asthenia—Methotrexate—colon cancer	0.00112	0.00146	CcSEcCtD
Glycopyrrolate—Pruritus—Methotrexate—colon cancer	0.00111	0.00144	CcSEcCtD
Glycopyrrolate—Dizziness—Methotrexate—colon cancer	0.00104	0.00134	CcSEcCtD
Glycopyrrolate—Vomiting—Methotrexate—colon cancer	0.000995	0.00129	CcSEcCtD
Glycopyrrolate—Rash—Methotrexate—colon cancer	0.000987	0.00128	CcSEcCtD
Glycopyrrolate—Dermatitis—Methotrexate—colon cancer	0.000986	0.00128	CcSEcCtD
Glycopyrrolate—Headache—Methotrexate—colon cancer	0.000981	0.00127	CcSEcCtD
Glycopyrrolate—Nausea—Methotrexate—colon cancer	0.00093	0.00121	CcSEcCtD
